Skip to content
Menu

Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $120

Benzinga Newsdesk 1 month ago

Analyst RatingsNewsPrice TargetHot

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Wells Fargo analyst Larry Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $119 to $120.

Wells Fargo analyst Larry Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $119 to $120.

Read at benzinga.com

← All stock news